Publication for SERPINA3 and CFB

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	SERPINA3	serpin family A member 3	12			[link]
hsa	CFB	complement factor B	629

Pubmed ID	Priority	Text
28252112	0.97	AACT, C1R, CFAB and CO4A negatively correlated to FA of the middle cerebellar peduncle in controls, with weak associations in MA and MAP groups.
	0.88	alpha 1-antichymotrypsin (AACT), complement C1r (C1R), complement factor B (CFAB), complement component 4 A (CO4A) were strongly associated with AD and FA in the middle cerebellar peduncle in controls, but not in the MA or MAP groups.
30157221	0.97	SERPINA3), CFB, and alpha-globin (HBA1) proteins were also observed.
	0.88	SERPINA3: alpha-1-antichytrypsin, CFB: complement factor B and HBA1: alpha-globin, IGLL1: Ig alpha-2-chain C region, IGLL5: Ig gamma-2-chain C region and ENS000223931: Ig heavy chain V-III TIL.
26908325	0.96	AACT, AGP1, CFB and HPX) were selected for further validation as serological markers for NSCLC and our results show that the expression level of AACT decreased significantly in early-stage NSCLC and was the best candidate for early diagnosis of NSCLC in the four tested proteins.
	0.94	AACT, AGP1, CFB and HPX, respectively; Right, the released iTRAQ reporter ions were used to provide the relative quantitation of each protein (Healthy, 114 isobaric tag; Benign, 115 isobaric tag; Stage IA, 116 isobaric tag; Stage IB, 117 isobaric tag).
	0.91	AACT, AGP1, CFB and HPX) were selected for further verification by western blotting.
	0.91	AACT, AGP1, CFB, HPX proteins.
	0.90	AACT, AGP1, CFB and HPX proteins were glycosylated in our samples, we treated our sera samples with PNGase F and immunoblotted the proteins.
	0.90	AACT, AGP1 and CFB were reduced significantly in cancer patients (Figure 4A-C), with significant decreases in very early Stage IA, whereas HPX were shown to be at slightly higher levels in tumour samples compared with those in benign diseases (Figure 4D).
	0.82	AACT, AGP1 and CFB showed good performance in very early Stage IA, and the AUC values were 0.826, 0.823 and 0.816, respectively (Supplementary Table S6).
	0.80	AACT, anti-AGP1, anti-CFB and anti-HPX antibodies.
	0.73	AACT, AGP1, CFB and HPX) for further biomarker validation and show these to be associated with cellular processes involved in tumour development and malignant cancer progression.
29927962	0.96	SERPINA3, TNFAIP6, C1R, SERPINE1, C3, THBD, PLAU, IRAK2, SOD2, PLSCR1, VNN1, SAA1, SAA2, PTX3, S100A9, S100A8, CFB, and IDO1), sebocytes via their products might also contribute to wound healing which is also a novel field yet to be characterized and could bring us closer to understand the background of acne-associated scarring.
31232531	0.91	Alpha-1-antichymotrypsin (ACT), Complement factor B (CFB), Plasminogen (PLG), Mannan-binding lectin serine protease 1 (MASP1) and plasma serine protease inhibitor (PSPI).
22355332	0.87	alpha-1-antichymotrypsin; cDNA FLJ55673, highly similar to complement factor B; cDNA FLJ54228, highly similar to leucine-rich alpha-2-glycoprotein; cDNA FLJ58564, highly similar to plasma protease C1 inhibitor; Ceruloplasmin, Complement C5 and Complement component C9b (green font), and were seen to be relatively decreased in expression in the non-progressing group compared with the BPH group, and relatively increased in expression as the cancer progressed i.e. were relatively increased in the progressing group and remained elevated in the metastatic group.
28007936	0.84	SERPINA3 (alpha-1-antitrypsin and alpha-1-antichymotrypsin) in group 3 and functionally related members of the complement cascade in group 4 (C4A, C4B, CFI, C8G, C8B, CFB).
30594242	0.83	alpha-1-antichymotrypsin, lysozyme C, Ig kappa chain V-II region TEW, complement factor B, afamin, antithrombin-III and coagulation factor XII.
25379033	0.77	CFB,complement factor B; CFH,complement factor H; FGA,fibrinogen alpha chain; FGB,fibrinogen beta chain; FGG,fibrinogen gamma chain; HP,haptoglobin; HPR,haptoglobin related protein; IGHA1,Ig alpha-1 chain C region; IGHA2,Ig alpha-2 chain C region; IGHG1,Ig gamma-1chain C region (G1m marker); IGHG2,Ig gamma-2 chain C region (G2m marker); IGHG3,Ig gamma-3 chain C region (G3m marker); IGHG4,Ig gamma-4 chain C region (G4m marker); IGK@,Ig kappa chain C region; IGKV4-1,Ig kappa chain variable 4-1; IGLC1,Ig lambda-1chain C region; IGLC2,Ig lambda-2 chain C region; ORM1,orosomucoid 1 or alpha-1-acid glycoprotein 1; SERPIN A1,serpin peptidase inhibitor, clade A member 1 or alpha-1-antitrypsin; SERPIN A3,serpin peptidase inhibitor, clade A member 3 or alpha-1-antichymotrypsin; VTN,vitronectin
28262744	0.63	alpha-1-antichymotrypsin (SERPINA3), and complement system proteins (Complement C1r subcomponent (C1R), Complement factor B (CFB), Complement component 9 (C9), Complement C1s subcomponent (C1S), Complement component 4-A (C4A), Complement component 4-B (C4B), and Complement component 7 (C7)) have been frequently detected in the acute phase of several diseases.
30841875	0.59	CFB, C3a, C5, C8b/C8g, C9, C1NH, C4BPA, CFH, CLU, VTN, VWF, SerpinC1, SerpinA3, MRC1, CD44, ApoA1, ApoA2, ApoA4, ApoB, ApoC1, ApoC3, ApoD, ApoE, A2M, SerpinA1, SerpinD1 and SerpinF1) and increased levels of 2 complement and complement-related proteins (C1QBP and SerpinH1) in lung cancer tissues compared to normal control tissues (Additional file 4: Figure S3 and Table S7).
28670579	0.55	CFB, SERPINA3, apolipoprotein A-I, IgG, complement component 5 (C5), immunoglobulin heavy constant alpha 1 (IgA), and histidine-rich glycoprotein.